JP2024509316A5 - - Google Patents

Info

Publication number
JP2024509316A5
JP2024509316A5 JP2023555709A JP2023555709A JP2024509316A5 JP 2024509316 A5 JP2024509316 A5 JP 2024509316A5 JP 2023555709 A JP2023555709 A JP 2023555709A JP 2023555709 A JP2023555709 A JP 2023555709A JP 2024509316 A5 JP2024509316 A5 JP 2024509316A5
Authority
JP
Japan
Prior art keywords
seq
nucleotide sequence
vector
identity
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509316A (ja
Filing date
Publication date
Priority claimed from PCT/GB2021/050633 external-priority patent/WO2021181118A1/en
Priority claimed from GBGB2103470.7A external-priority patent/GB202103470D0/en
Priority claimed from PCT/GB2021/051668 external-priority patent/WO2022003357A1/en
Application filed filed Critical
Publication of JP2024509316A publication Critical patent/JP2024509316A/ja
Publication of JP2024509316A5 publication Critical patent/JP2024509316A5/ja
Pending legal-status Critical Current

Links

JP2023555709A 2021-03-12 2022-03-14 最小ネフリンプロモーター Pending JP2024509316A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2103470.7 2021-03-12
GBPCT/GB2021/050633 2021-03-12
PCT/GB2021/050633 WO2021181118A1 (en) 2020-03-12 2021-03-12 Gene therapy
GBGB2103470.7A GB202103470D0 (en) 2021-03-12 2021-03-12 Promoter
PCT/GB2021/051668 WO2022003357A1 (en) 2020-06-30 2021-06-30 Vector
GBPCT/GB2021/051668 2021-06-30
PCT/GB2022/050649 WO2022189811A1 (en) 2021-03-12 2022-03-14 Minimal nephrin promoter

Publications (2)

Publication Number Publication Date
JP2024509316A JP2024509316A (ja) 2024-02-29
JP2024509316A5 true JP2024509316A5 (https=) 2025-03-21

Family

ID=75623235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555709A Pending JP2024509316A (ja) 2021-03-12 2022-03-14 最小ネフリンプロモーター

Country Status (18)

Country Link
US (1) US20250283072A1 (https=)
EP (2) EP4722371A2 (https=)
JP (1) JP2024509316A (https=)
KR (1) KR20230161459A (https=)
CN (1) CN117377770A (https=)
AU (1) AU2022235209A1 (https=)
BR (1) BR112023018362A2 (https=)
CA (1) CA3211566A1 (https=)
DK (1) DK4305181T3 (https=)
ES (1) ES3056304T3 (https=)
FI (1) FI4305181T3 (https=)
GB (1) GB202103470D0 (https=)
HR (1) HRP20251561T1 (https=)
IL (1) IL305714A (https=)
MX (1) MX2023010573A (https=)
PL (1) PL4305181T3 (https=)
PT (1) PT4305181T (https=)
WO (1) WO2022189811A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003109D0 (en) * 2020-03-04 2020-04-15 Univ Bristol Gene therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202217332D0 (en) * 2022-11-18 2023-01-04 Univ Bristol Methods
EP4397976A1 (en) * 2023-01-09 2024-07-10 x-kidney diagnostics GmbH Biomarkers for the pre-clinical and/or early-stage detection and/or diagnosis of kidney diseases
GB202309909D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Regulatory elements
GB202309908D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
GB202309913D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome
GB202309914D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Promoters

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (zh) 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
GB201900702D0 (en) * 2019-01-18 2019-03-06 Univ Bristol Therapy

Similar Documents

Publication Publication Date Title
JP2024509316A5 (https=)
FI4305181T3 (fi) Minimaalinen nefriinipromoottori
ES2618851T3 (es) Purificación de vectores retrovirales
JP2022529631A5 (https=)
RU2014138491A (ru) Композиции и способы лечения гемоглобинопатии
AU2019350871B2 (en) Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder
JP2024095717A5 (https=)
JP2024099770A5 (https=)
JP2020522269A5 (https=)
RU2019133002A (ru) ЭКСПРЕССИОННЫЕ КАССЕТЫ MeCP2
HRP20241180T1 (hr) Modificirani faktor ix, te pripravci, postupci i upotreba za prijenos gena u stanice, organe i tkiva
JP2018522529A5 (https=)
JP2005502355A5 (https=)
JP2024523394A5 (https=)
CA2370103A1 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
JP5670330B2 (ja) 最適化したプロモーター配列
JP2022530095A5 (https=)
JP2023551874A5 (https=)
JP2021536250A5 (https=)
JP2023545433A5 (https=)
US20210332344A1 (en) Directed modification of rna
JP2023551873A5 (https=)
CN116949012B (zh) 一种融合蛋白及其应用
JP2023539631A5 (https=)
JP2023534293A5 (https=)